Suggested remit - To appraise the clinical and cost effectiveness of angiotensin ll within its marketing authorisation for the treatment of hypotension adults with septic or other distributive shock who remain hypotensive following catecholamines and other vasopressor therapies
 
Status Proposed
Process STA 2018
ID number 1588

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
16 July 2019 (14:00) Scoping workshop (Manchester)
24 May 2019 - 24 June 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance